$EVFM
Evofem Biosciences, Inc. Stock $evfm

$evfm Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000161883521000099 Filed on May 06, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$1.105M	$0.00
YoY Change
Cost Of Revenue	$506.0K	$0.00
YoY Change
Gross Profit	$599.0K	$0.00
YoY Change
Gross Profit Margin	54.21%
Selling, General & Admin	$38.21M	$15.00M
YoY Change	154.78%	161.14%
% of Gross Profit	6378.8%
Research & Development	$7.262M	$4.247M
YoY Change	70.99%	-46.17%
% of Gross Profit	1212.35%
Depreciation & Amortization	$200.0K	$70.00K
YoY Change	185.71%	0.0%
% of Gross Profit	33.39%
Operating Expenses	$45.98M	$19.24M
YoY Change	138.92%	41.17%
Operating Profit	-$44.87M	-$19.24M
YoY Change	133.17%	41.17%
Interest Expense	$1.152M	$0.00
YoY Change		-100.0%
% of Operating Profit
Other Income/Expense, Net	-$1.280M	$98.00K
YoY Change	-1406.12%	-102.21%
Pretax Income	-$46.15M	-$19.15M
YoY Change	141.05%	5.97%
Income Tax	-$1.000K	$0.00
% Of Pretax Income
Net Earnings	-$46.15M	-$19.15M
YoY Change	141.05%	5.97%
Net Earnings / Revenue	-4176.56%
Basic Earnings Per Share	-$8.46
Diluted Earnings Per Share	-$8.46	-$397.3K
COMMON SHARES
Basic Shares Outstanding	5.456M shares	49.59M shares
Diluted Shares Outstanding	5.456M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$45.30M	$10.40M
YoY Change	335.58%	5100.0%
Cash & Equivalents	$45.32M	$8.785M
Short-Term Investments		$1.600M
Other Short-Term Assets	$23.10M	$3.000M
YoY Change	670.0%	200.0%
Inventory	$8.990M
Prepaid Expenses
Receivables	$2.914M
Other Receivables	$0.00
Total Short-Term Assets	$80.34M	$13.72M
YoY Change	485.66%	870.77%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.614M	$622.0K
YoY Change	802.57%	18.03%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.022M	$1.044M
YoY Change	-2.11%	60.86%
Total Long-Term Assets	$13.13M	$1.928M
YoY Change	580.96%	5.88%
TOTAL ASSETS
Total Short-Term Assets	$80.34M	$13.72M
Total Long-Term Assets	$13.13M	$1.928M
Total Assets	$93.46M	$15.65M
YoY Change	497.4%	383.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.501M	$7.120M
YoY Change	-8.69%	-40.33%
Accrued Expenses	$8.978M	$2.499M
YoY Change	259.26%	-78.54%
Deferred Revenue
YoY Change
Short-Term Debt	$53.20M	$0.00
YoY Change		-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$75.71M	$14.46M
YoY Change	423.52%	-54.93%
LONG-TERM LIABILITIES
Long-Term Debt	$25.70M	$0.00
YoY Change
Other Long-Term Liabilities	$5.700M	$200.0K
YoY Change	2750.0%
Total Long-Term Liabilities	$31.40M	$200.0K
YoY Change	15600.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$75.71M	$14.46M
Total Long-Term Liabilities	$31.40M	$200.0K
Total Liabilities	$107.1M	$14.62M
YoY Change	632.37%	-54.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$701.6M	-$532.3M
YoY Change	31.81%	17.97%
Common Stock	$688.0M	$533.3M
YoY Change	29.0%	26.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$13.64M	$1.021M
YoY Change
Total Liabilities & Shareholders Equity	$93.46M	$15.65M
YoY Change	497.4%	383.77%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$46.15M	-$19.15M
YoY Change	141.05%	5.97%
Depreciation, Depletion And Amortization	$200.0K	$70.00K
YoY Change	185.71%	0.0%
Cash From Operating Activities	-$34.46M	-$14.88M
YoY Change	131.63%	93.75%
INVESTING ACTIVITIES
Capital Expenditures	$956.0K	$95.00K
YoY Change	906.32%
Acquisitions
YoY Change
Other Investing Activities	$250.0K	$6.900M
YoY Change	-96.38%	2660.0%
Cash From Investing Activities	-$706.0K	$6.902M
YoY Change	-110.23%	2660.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$28.05M	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$28.01M	$1.364M
YoY Change	1953.23%	-78.24%
NET CHANGE
Cash From Operating Activities	-$34.46M	-$14.88M
Cash From Investing Activities	-$706.0K	$6.902M
Cash From Financing Activities	$28.01M	$1.364M
Net Change In Cash	-$7.158M	-$6.610M
YoY Change	8.29%	469.34%
FREE CASH FLOW
Cash From Operating Activities	-$34.46M	-$14.88M
Capital Expenditures	$956.0K	$95.00K
Free Cash Flow	-$35.41M	-$14.97M
YoY Change	136.55%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001618835
CY2020Q2	evfm	Class Of Warrant Or Right Vesting Term ClassOfWarrantOrRightVestingTerm	P5Y
CY2020Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	0.001	shares
CY2020Q1	evfm	Class Of Warrant Or Right Purchase Price ClassOfWarrantOrRightPurchasePrice	17.50
CY2020Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.0175
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8527075
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-36754
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	EVOFEM BIOSCIENCES, INC.
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	12400 High Bluff Drive
CY2021Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 600
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92130
CY2021Q1	dei	City Area Code CityAreaCode	858
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	550-1900
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	102835674	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45318000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	48892000	USD
CY2021Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	18975000	USD
CY2020Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	22559000	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2914000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1067000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	8990000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	7162000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4138000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18050000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	80335000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	97730000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5614000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4334000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6493000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6856000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1022000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1048000	USD
CY2021Q1	us-gaap	Assets Assets	93464000	USD
CY2020Q4	us-gaap	Assets Assets	109968000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	6501000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10641000	USD
CY2021Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	53218000	USD
CY2020Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	52409000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8978000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4476000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3004000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	6514000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2456000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2290000	USD
CY2021Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1549000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	953000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	75706000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	77283000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5602000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6030000	USD
CY2021Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	25697000	USD
CY2020Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	25211000	USD
CY2021Q1	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	97000	USD
CY2020Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	97000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	107102000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	108621000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000000	shares
CY2021Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	5000000	shares
CY2021Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	0	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	100264246	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	100264246	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	81351533	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	81351533	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	10000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	8000	USD
CY2021Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	687991000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	656827000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-701639000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-655488000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-13638000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1347000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	93464000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	109968000	USD
CY2021Q1	us-gaap	Revenues Revenues	1105000	USD
CY2020Q1	us-gaap	Revenues Revenues	0	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	506000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	0	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7262000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7142000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4247000	USD
CY2021Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	30525000	USD
CY2020Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7855000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7684000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	45977000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	19244000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-44872000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-19244000	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	7000	USD
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	102000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1145000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4000	USD
CY2021Q1	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-142000	USD
CY2020Q1	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1280000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	98000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3464000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-46151000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	81843319	shares
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-13638000	USD
CY2020Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	25000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	15636000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	73000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-46152000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19146000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-46151000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-19146000	USD
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	48195951	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	1347000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	27709000	USD
CY2021Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	7000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3401000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-19146000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	1021000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-46151000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-19146000	USD
CY2021Q1	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-142000	USD
CY2020Q1	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3464000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3401000	USD
CY2021Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	195000	USD
CY2020Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	69000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	330000	USD
CY2020Q1	us-gaap	Lease Cost LeaseCost	164000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	1152000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	0	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1847000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1676000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	0	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-13606000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1027000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-4647000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	996000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4713000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-205000	USD
CY2021Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-3510000	USD
CY2020Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1069000	USD
CY2021Q1	evfm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	229000	USD
CY2020Q1	evfm	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	197000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34458000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14876000	USD
CY2021Q1	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	250000	USD
CY2020Q1	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	250000	USD
CY2021Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	0	USD
CY2020Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	6747000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	956000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	95000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-706000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	6902000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28050000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021Q1	evfm	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	USD
CY2020Q1	evfm	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	1424000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	160000	USD
CY2021Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	37000	USD
CY2020Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	195000	USD
CY2021Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	7000	USD
CY2020Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	25000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28006000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1364000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7158000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6610000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72251000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16625000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65093000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10015000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	266000	USD
CY2021Q1	evfm	Deferred Offering Costs Included In Accounts Payable And Accrued Expense DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense	304000	USD
CY2020Q1	evfm	Deferred Offering Costs Included In Accounts Payable And Accrued Expense DeferredOfferingCostsIncludedInAccountsPayableAndAccruedExpense	13000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	519000	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	201000	USD
CY2020Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	103700000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	45300000	USD
CY2021Q1	us-gaap	Restricted Cash RestrictedCash	18600000	USD
CY2021Q1	evfm	Working Capital Surplus Deficit WorkingCapitalSurplusDeficit	4600000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-701600000	USD
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the notes thereto.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ignificant estimates affecting amounts reported or disclosed in the condensed consolidated financial statements include, but are not limited to: the assumptions used in measuring the revenue gross-to-net variable consideration items, the trade accounts receivable credit loss reserve estimate, the discount rate used in estimating the fair value of the lease right</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use assets and lease liabilities, the assumptions used in estimating the fair value of convertible notes, warrants and purchase rights issued, the useful lives of property and equipment, the recoverability of long-lived assets, clinical trial accruals, the assumptions used in estimating the fair value of stock-based compensation expense and in assessing the probability of achieving certain milestones associated with the performance-based restricted stock awards (performance-based RSAs). These assumptions are more fully described in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8657ea44b04a4e039df15bb91db69e6f_40" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 3- Revenue</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8657ea44b04a4e039df15bb91db69e6f_46" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 5- Convertible Notes</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8657ea44b04a4e039df15bb91db69e6f_55" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 7- Fair Value of Financial Instruments</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8657ea44b04a4e039df15bb91db69e6f_58" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 8- Commitments and Contingencies</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i8657ea44b04a4e039df15bb91db69e6f_73" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Note 11- Stock-based Compensation</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of assets and liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.</span></div>
CY2021Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	18975000	USD
CY2020Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	480000	USD
CY2021Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2021Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking, time deposit and investment accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the consolidated balance sheets.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances due to the financial position of the depository institutions in which these deposits are held.</span></div>The Company is also subject to credit risk related to its trade accounts receivable from product sales. Its customers are located in the United States and consist of wholesale distributors and a specialty retail pharmacy. The Company extends credit to its customers in the normal course of business after evaluating their overall financial condition and evaluates the collectability of its accounts receivable by periodically reviewing the age of the receivables, the financial condition of its customers, and its past collection experience. Historically, the Company has not experienced any credit losses.
CY2021Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	25000000.0	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	45318000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8785000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65093000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10015000	USD
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23902219	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23902219	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14512911	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14512911	shares
CY2021Q1	evfm	Product Revenue Variable Consideration Liability Current ProductRevenueVariableConsiderationLiabilityCurrent	1600000	USD
CY2021Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	486000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	332000	USD
CY2021Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	4173000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	4162000	USD
CY2021Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4331000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2668000	USD
CY2021Q1	us-gaap	Inventory Gross InventoryGross	8990000	USD
CY2020Q4	us-gaap	Inventory Gross InventoryGross	7162000	USD
CY2020Q2	evfm	Securities Sold Under Purchase Agreement SecuritiesSoldUnderPurchaseAgreement	15000000.0	USD
CY2020Q2	evfm	Purchase Agreement Maximum Amount Of Securities Purchasable Under Agreement PurchaseAgreementMaximumAmountOfSecuritiesPurchasableUnderAgreement	10000000.0	USD
CY2020Q2	evfm	Purchase Agreement Threshold Amount Of Aggregate Gross Proceeds From Future Sale Of Equity Securities PurchaseAgreementThresholdAmountOfAggregateGrossProceedsFromFutureSaleOfEquitySecurities	100000000.0	USD
CY2020Q2	evfm	Purchase Agreement Maximum Amount Of Securities Purchasable Under Agreement PurchaseAgreementMaximumAmountOfSecuritiesPurchasableUnderAgreement	10000000.0	USD
CY2020Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.44
CY2020Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.44
CY2020Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	58100000	USD
CY2020Q2	evfm	Class Of Warrant Or Right Liability ClassOfWarrantOrRightLiability	46700000	USD
CY2020Q2	evfm	Loss On Issuance Of Financial Instruments LossOnIssuanceOfFinancialInstruments	64000000.0	USD
CY2020Q2	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	34100000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	15800000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	11000000.0	USD
CY2021Q1	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-100000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4138000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	18050000	USD
CY2016Q3	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	1900000	USD
CY2016Q3	us-gaap	Proceeds From Sales Of Business Affiliate And Productive Assets ProceedsFromSalesOfBusinessAffiliateAndProductiveAssets	600000	USD
CY2016Q3	us-gaap	Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet	1300000	USD
CY2016Q3	evfm	Disposal Group Including Discontinued Operation Consideration Receivable Stated Rate DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableStatedRate	0.050
CY2016Q3	evfm	Disposal Group Including Discontinued Operation Consideration Receivable Annual Principal Payment DisposalGroupIncludingDiscontinuedOperationConsiderationReceivableAnnualPrincipalPayment	300000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6960000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5485000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1346000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1151000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5614000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4334000	USD
CY2021Q1	us-gaap	Depreciation Nonproduction DepreciationNonproduction	200000	USD
CY2020Q1	us-gaap	Depreciation Nonproduction DepreciationNonproduction	100000	USD
CY2021Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	800000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	800000	USD
CY2021Q1	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	188000	USD
CY2020Q4	us-gaap	Prepaid Expense Noncurrent PrepaidExpenseNoncurrent	214000	USD
CY2021Q1	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	34000	USD
CY2020Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	34000	USD
CY2021Q1	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	1022000	USD
CY2020Q4	us-gaap	Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment	1048000	USD
CY2021Q1	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	2977000	USD
CY2020Q4	evfm	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	1417000	USD
CY2021Q1	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	3558000	USD
CY2020Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	564000	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1156000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1631000	USD
CY2021Q1	evfm	Accrued Manufacturing Related Costs Current AccruedManufacturingRelatedCostsCurrent	452000	USD
CY2020Q4	evfm	Accrued Manufacturing Related Costs Current AccruedManufacturingRelatedCostsCurrent	498000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	835000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	366000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8978000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4476000	USD
CY2021Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	62667000	USD
CY2021Q1	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	50894000	USD
CY2021Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	50894000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	70233000	USD
CY2020Q4	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	50752000	USD
CY2020Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	50752000	USD
CY2021Q1	evfm	Lessee Operating Lease Number Of Vehicles Leased LesseeOperatingLeaseNumberOfVehiclesLeased	74	vehicle
CY2019Q4	evfm	Office Square Footage OfficeSquareFootage	24474	sqft
CY2019Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2020Q2	evfm	Office Square Footage OfficeSquareFootage	8816	sqft
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	593000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	180000	USD
CY2021Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10426107	shares
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y2M19D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y5M4D
CY2021Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.12
CY2020Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.12
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1961000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2497000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2166000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2192000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1502000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	10318000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2260000	USD
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	8058000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	486000	USD
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	201000	USD
CY2020Q4	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	0	claim
CY2021Q1	us-gaap	Loss Contingency Pending Claims Number LossContingencyPendingClaimsNumber	0	claim
CY2019Q2	evfm	Compensation Agreement Potential Bonus As A Percent Of Consulting Fees Earned CompensationAgreementPotentialBonusAsAPercentOfConsultingFeesEarned	1
CY2020Q1	evfm	Stock Dividend Rights Issued Per Share Of Common Stock Held StockDividendRightsIssuedPerShareOfCommonStockHeld	1
CY2021Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.54
CY2021Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10426107	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	evfm	Common Stock Reserved Upon Exercise Of Common Stock Warrants CommonStockReservedUponExerciseOfCommonStockWarrants	10426107	shares
CY2021Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	25402582	shares
CY2020Q1	evfm	Stock Dividends Right StockDividendsRight	1	shares
CY2020Q1	evfm	Class Of Warrant Or Right Purchase Price ClassOfWarrantOrRightPurchasePrice	17.50
CY2020Q1	evfm	Class Of Warrant Or Right Vesting Term For Beneficial Ownership Threshold ClassOfWarrantOrRightVestingTermForBeneficialOwnershipThreshold	P10D
CY2020Q1	evfm	Class Of Warrant Or Right Right Agreement Beneficial Ownership Threshold ClassOfWarrantOrRightRightAgreementBeneficialOwnershipThreshold	0.32
CY2020Q1	evfm	Class Of Warrant Or Right Vesting Term ClassOfWarrantOrRightVestingTerm	P10D
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3464000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3401000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2478025	shares
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1475485	shares

Files In Submission

Name	View Source	Status
0001618835-21-000099-index-headers.html	Edgar Link	pending
0001618835-21-000099-index.html	Edgar Link	pending
0001618835-21-000099.txt	Edgar Link	pending
0001618835-21-000099-xbrl.zip	Edgar Link	pending
evfm-20210331.htm	Edgar Link	pending
evfm-20210331.xsd	Edgar Link	pending
evfm-20210331_cal.xml	Edgar Link	unprocessable
evfm-20210331_def.xml	Edgar Link	unprocessable
evfm-20210331_htm.xml	Edgar Link	completed
evfm-20210331_lab.xml	Edgar Link	unprocessable
evfm-20210331_pre.xml	Edgar Link	unprocessable
evfm-3312021ex312.htm	Edgar Link	pending
evfm-3312021ex321.htm	Edgar Link	pending
evfm-3312021xex311.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EVFM
Evofem Biosciences, Inc. Stock $evfm

2021 Q1 Form 10-Q Financial Statement

#000161883521000099 Filed on May 06, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM Evofem Biosciences, Inc. Stock $evfm

2021 Q1 Form 10-Q Financial Statement

#000161883521000099 Filed on May 06, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM
Evofem Biosciences, Inc. Stock $evfm